APLLTD2026-06-072026-06-07APLLTD2026-06-07APLLTD2026-06-072026-06-07PartiesOfTheAgreementDomain1APLLTD2026-06-07PartiesOfTheAgreementDomain1APLLTD2026-06-072026-06-07PartiesOfTheAgreementDomain2APLLTD2026-06-07PartiesOfTheAgreementDomain2APLLTD2026-06-072026-06-07PartiesOfTheAgreementDomain3APLLTD2026-06-07PartiesOfTheAgreementDomain3APLLTD2026-06-072026-06-07PartiesOfTheAgreementDomain4APLLTD2026-06-07PartiesOfTheAgreementDomain4xbrli:pureAPLLTDAlembic Pharmaceuticals LimitedNewShareholder agreementsExecution of agreementListed Entityfalse2026-06-0520:00:00true2026-06-07Investment in Canadian Corporation to establish a platform for development, commercialization, distribution and marketing of pharmaceutical products focused on the Canadian market. The shareholding of the Corporation held by each Party shall be as under: a) Alembic Pharmaceuticals Limited (45%); b) Difgen Holdings LLC (45%); and (c) Others: 10%trueNo Impact.4Alembic Pharmaceuticals LimitedParty entering into the agreement0.45falseDifgen Holdings LLCParty entering into the agreement0.45falseMr. Sukhad JunejaParty entering into the agreement0.1false17989377 CANADA INC.Counterparties to the agreementNot Applicablefalse2026-06-05Investment in Canadian Corporation to establish a platform for development, commercialization, distribution and marketing of pharmaceutical products focused on the Canadian market.The board of directors of the Canadian Corporation comprises nominee directors of the shareholders along with an independent director. The agreement also provides for customary shareholder rights including participation in key decision matters.falseNot Applicable